Alterations of the mTOR pathway seem to be involved in the acquisition of a phenotype responsible for treatment resistance [15], whereas mTOR inactivation has been reported to reduce the risk of endometrial cancer [16]. The gene discussed is MTOR; the disease is endometrial cancer.